What is OmniAb?
Founded in 2007, OmniAb operates at the forefront of biotechnology, providing pharmaceutical partners with advanced antibody discovery platforms. The company leverages proprietary transgenic animal technologies, including OmniRat, OmniChicken, OmniMouse, OmniFlic, OmniClic, and OmniTaur, which are engineered to generate human sequence antibodies essential for therapeutic applications. Complementing its biological systems, OmniAb integrates computational antigen design, sophisticated immunization techniques, and high-throughput screening to expedite the identification of novel antibodies. Furthermore, the OmniDeep suite of in silico tools enhances therapeutic discovery and optimization processes. OmniAb's customizable solutions cater to a range of antibody modalities, such as bispecific antibodies and antibody-drug conjugates, supporting critical pharmaceutical research and development initiatives.
How much funding has OmniAb raised?
OmniAb has raised a total of $30M across 1 funding round:
Private Equity
$30M
Private Equity (2025): $30M, investors not publicly disclosed
What's next for OmniAb?
The substantial enterprise-level funding and recent strategic investment position OmniAb for accelerated growth and innovation in the competitive antibody discovery market. This capital infusion is expected to fuel further development of its proprietary technologies, expand its research and development capabilities, and strengthen its partnerships within the pharmaceutical sector. OmniAb's focus on advanced platforms for therapeutic antibodies suggests a strategic trajectory aimed at addressing unmet medical needs and solidifying its market leadership in antibody-based drug development.
See full OmniAb company page
